Clinical Trials · NCT03471728

Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)

Name: Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedN/ALinaclotide

Phase: N/A
Recruitment status: Completed
Sponsor: Astellas Pharma Inc
Enrollment: 2,475
Start date: Oct 2017
Locations: 47 sites, Japan
Primary endpoint: Incidence of diarrhea

View Linaclotide compound reference